<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300274</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001A2310</org_study_id>
    <nct_id>NCT00300274</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection</brief_title>
  <official_title>A 24-month, Multi-center, Randomized, Open-label, Non-inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-controlled Everolimus With Reduced Cyclosporine Versus 3.0 g Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Heart Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This trial was to examine the impact of everolimus and reduced dose of cyclosporine on
      efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in
      heart transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Composite Efficacy Failure at 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <description>Composite efficacy failure was defined as Biopsy Proven Acute Rejection(BPAR) of International Society for Heart and Lung Transplantation(ISHLT) grade ≥3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.
Identification of acute rejection was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤30% or 25% lower than Baseline or Fractional shortening ≤20% or 25% lower than Baseline and/or use of inotropic treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <description>Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 316 (start day of the Month 12 visit window).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months</measure>
    <time_frame>12 Months</time_frame>
    <description>GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Average Maximum Intimal Thickness at Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Maximum intimal thickness was assessed using Intravascular Ultrasound (IVUS). IVUS is a technique for taking ultrasound pictures of the wall of an artery from inside the artery itself. It shows the thickness of the artery wall and any narrowing of the artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>Cardiac allograft vasculopathy is defined as a 0.5 mm increase in maximum intimal thickness as measured by Intravascular Ultrasound (IVUS) in at least one matched slice between baseline and Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/or use of inotropic treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Composite Efficacy Failure at 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>Composite efficacy failure was defined as Biopsy Proven Acute Rejection (BPAR) of International Society for Heart and Lung Transplantation grade ≥ 3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.
Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline and/or use of inotropic treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 631 (start day of 24 Month visit window).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months</measure>
    <time_frame>24 Months</time_frame>
    <description>GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R
C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/ or use of inotropic treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">721</enrollment>
  <condition>Graft Rejection</condition>
  <arm_group>
    <arm_group_label>everolimus 1.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>everolimus 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Randomization of new patients in this arm was prematurely stopped as of 27 March 2008 due to high mortality rate, as per Data Monitoring Committee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.</description>
    <arm_group_label>everolimus 1.5 mg</arm_group_label>
    <arm_group_label>everolimus 3.0 mg</arm_group_label>
    <other_name>Zortress®</other_name>
    <other_name>Certican®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil supplied as 500 mg tablets.</description>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <other_name>Cellcept®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.</description>
    <arm_group_label>everolimus 1.5 mg</arm_group_label>
    <arm_group_label>everolimus 3.0 mg</arm_group_label>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <other_name>Neoral®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroids</intervention_name>
    <description>Corticosteroids standard dose.</description>
    <arm_group_label>everolimus 1.5 mg</arm_group_label>
    <arm_group_label>everolimus 3.0 mg</arm_group_label>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female cardiac recipients 18-70 years of age undergoing primary heart
             transplantation.

          -  The graft must be functional at time of randomization.

        Exclusion Criteria:

          -  Patients who are recipients of multiple solid organ transplants or tissue transplants
             or have previously received organ transplants.

          -  Patients who are recipients of ABO incompatible transplants.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford U Sch, Falk Cardiovasular Research Ctr.</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola Univerisity Medical School</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Recanati Miller Transplant Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Division of Cardiology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Heart Failure Research</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiovascular Consultants</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch, Div of Cardio Thoracic</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital/DeBakey Heart Failure Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison Medical School</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center Cardiac Services</name>
      <address>
        <city>Milwakee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Favalaro</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Halifax Infirmary</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Univ. de cardiologie et pneumologie de Quebec</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cardiologique de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg Hopital Civil Medicale B</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- u. Diabeteszentrum NRW/Ruhr-Univ. Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Med. Hochschule</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. di Bologna Policl. S. Orsola-Malpighi Univ. degli Studi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Brotzu</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.-Universita di Padova-Universita degli Studi</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fodazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Camillo-Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliero-Universitaria S. Giovanni Battista di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet, Hjertemedisinskavdeling</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center of Puerto Rico and the Caribbean</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2006</study_first_submitted>
  <study_first_submitted_qc>March 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2006</study_first_posted>
  <results_first_submitted>July 6, 2012</results_first_submitted>
  <results_first_submitted_qc>July 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2012</results_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Everolimus</keyword>
  <keyword>heart transplant</keyword>
  <keyword>heart disease</keyword>
  <keyword>transplantation</keyword>
  <keyword>heart IVUS assessment at 12 months</keyword>
  <keyword>rate of graft loss</keyword>
  <keyword>acute rejection episodes</keyword>
  <keyword>survival</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Everolimus 1.5 mg</title>
          <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
        </group>
        <group group_id="P2">
          <title>Everolimus 3.0 mg</title>
          <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
        </group>
        <group group_id="P3">
          <title>Mycophenolate Mofetil</title>
          <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="271"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 12 Month</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="248"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="236"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Re-transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus 1.5 mg</title>
          <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
        </group>
        <group group_id="B2">
          <title>Everolimus 3.0 mg</title>
          <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
        </group>
        <group group_id="B3">
          <title>Mycophenolate Mofetil</title>
          <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="282"/>
            <count group_id="B2" value="168"/>
            <count group_id="B3" value="271"/>
            <count group_id="B4" value="721"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.1" spread="10.99"/>
                    <measurement group_id="B2" value="48.9" spread="12.06"/>
                    <measurement group_id="B3" value="50.2" spread="11.88"/>
                    <measurement group_id="B4" value="50.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="220"/>
                    <measurement group_id="B4" value="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Composite Efficacy Failure at 12 Months</title>
        <description>Composite efficacy failure was defined as Biopsy Proven Acute Rejection(BPAR) of International Society for Heart and Lung Transplantation(ISHLT) grade ≥3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.
Identification of acute rejection was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤30% or 25% lower than Baseline or Fractional shortening ≤20% or 25% lower than Baseline and/or use of inotropic treatment.</description>
        <time_frame>12 Months</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Efficacy Failure at 12 Months</title>
          <description>Composite efficacy failure was defined as Biopsy Proven Acute Rejection(BPAR) of International Society for Heart and Lung Transplantation(ISHLT) grade ≥3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.
Identification of acute rejection was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤30% or 25% lower than Baseline or Fractional shortening ≤20% or 25% lower than Baseline and/or use of inotropic treatment.</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="35.1"/>
                    <measurement group_id="O3" value="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months</title>
        <description>Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 316 (start day of the Month 12 visit window).</description>
        <time_frame>12 Months</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months</title>
          <description>Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 316 (start day of the Month 12 visit window).</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="11.9"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months</title>
        <description>GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1</description>
        <time_frame>12 Months</time_frame>
        <population>Participants from the intent-to-treat population (all randomized participants) with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months</title>
          <description>GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1</description>
          <population>Participants from the intent-to-treat population (all randomized participants) with data available for analysis.</population>
          <units>mL/min/1.73^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.21" spread="23.113"/>
                    <measurement group_id="O2" value="59.78" spread="23.141"/>
                    <measurement group_id="O3" value="64.37" spread="28.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Average Maximum Intimal Thickness at Month 12</title>
        <description>Maximum intimal thickness was assessed using Intravascular Ultrasound (IVUS). IVUS is a technique for taking ultrasound pictures of the wall of an artery from inside the artery itself. It shows the thickness of the artery wall and any narrowing of the artery.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>IVUS population consisted of randomized patients who had a minimum of 11 matched slices between IVUS images from Baseline and from Month 12 (IVUS Centers).</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Average Maximum Intimal Thickness at Month 12</title>
          <description>Maximum intimal thickness was assessed using Intravascular Ultrasound (IVUS). IVUS is a technique for taking ultrasound pictures of the wall of an artery from inside the artery itself. It shows the thickness of the artery wall and any narrowing of the artery.</description>
          <population>IVUS population consisted of randomized patients who had a minimum of 11 matched slices between IVUS images from Baseline and from Month 12 (IVUS Centers).</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.052"/>
                    <measurement group_id="O2" value="0.04" spread="0.06"/>
                    <measurement group_id="O3" value="0.07" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12</title>
        <description>Cardiac allograft vasculopathy is defined as a 0.5 mm increase in maximum intimal thickness as measured by Intravascular Ultrasound (IVUS) in at least one matched slice between baseline and Month 12.</description>
        <time_frame>12 Months</time_frame>
        <population>IVUS population consisted of randomized patients who had a minimum of 11 matched slices between IVUS images from Baseline and from Month 12 (IVUS centers).</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12</title>
          <description>Cardiac allograft vasculopathy is defined as a 0.5 mm increase in maximum intimal thickness as measured by Intravascular Ultrasound (IVUS) in at least one matched slice between baseline and Month 12.</description>
          <population>IVUS population consisted of randomized patients who had a minimum of 11 matched slices between IVUS images from Baseline and from Month 12 (IVUS centers).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="21.6"/>
                    <measurement group_id="O3" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12</title>
        <description>Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/or use of inotropic treatment.</description>
        <time_frame>12 Months</time_frame>
        <population>Intent-to-treat population includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12</title>
          <description>Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/or use of inotropic treatment.</description>
          <population>Intent-to-treat population includes all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AR associated with HDC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPAR of ISHLT ≥ 3A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss/re-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Composite Efficacy Failure at 24 Months</title>
        <description>Composite efficacy failure was defined as Biopsy Proven Acute Rejection (BPAR) of International Society for Heart and Lung Transplantation grade ≥ 3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.
Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline and/or use of inotropic treatment.</description>
        <time_frame>24 Months</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Efficacy Failure at 24 Months</title>
          <description>Composite efficacy failure was defined as Biopsy Proven Acute Rejection (BPAR) of International Society for Heart and Lung Transplantation grade ≥ 3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.
Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline and/or use of inotropic treatment.</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4"/>
                    <measurement group_id="O2" value="41.1"/>
                    <measurement group_id="O3" value="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months</title>
        <description>Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 631 (start day of 24 Month visit window).</description>
        <time_frame>24 Months</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months</title>
          <description>Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 631 (start day of 24 Month visit window).</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="16.1"/>
                    <measurement group_id="O3" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months</title>
        <description>GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R
C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1</description>
        <time_frame>24 Months</time_frame>
        <population>Participants from the intent-to-treat population (all randomized participants) with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months</title>
          <description>GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R
C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1</description>
          <population>Participants from the intent-to-treat population (all randomized participants) with data available for analysis.</population>
          <units>mL/min/1.73^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="227"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.50" spread="22.438"/>
                    <measurement group_id="O2" value="61.84" spread="25.247"/>
                    <measurement group_id="O3" value="64.52" spread="23.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24</title>
        <description>Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/ or use of inotropic treatment.</description>
        <time_frame>24 Months</time_frame>
        <population>Intent-to-treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus 1.5 mg</title>
            <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus 3.0 mg</title>
            <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
          </group>
          <group group_id="O3">
            <title>Mycophenolate Mofetil</title>
            <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24</title>
          <description>Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.
Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/ or use of inotropic treatment.</description>
          <population>Intent-to-treat population included all randomized participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AR associated with HDC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPAR of ISHLT grade ≥ 3A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="11.9"/>
                    <measurement group_id="O3" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss/re-transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Everolimus 1.5 mg</title>
          <description>Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.</description>
        </group>
        <group group_id="E2">
          <title>Everolimus 3.0 mg</title>
          <description>Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.</description>
        </group>
        <group group_id="E3">
          <title>Mycophenolate Mofetil</title>
          <description>Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dilatation atrial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pericardial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ventricular asystole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Retinal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gingival hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Stomatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Concomitant disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Crepitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Heart transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Acute pulmonary histoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Candida pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebral aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Enterobacter pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fungal abscess central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fungal peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fungal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Intraspinal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Listeriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mycobacterium chelonei infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Myocarditis mycotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pericarditis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Purulent pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Spinal cord infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Staphylococcal mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Complications of transplanted heart</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dislocation of sternum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Post procedural diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Atrial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cells in urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Central venous pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Culture wound positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Immunosuppressant drug level</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Immunosuppressant drug level decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Immunosuppressant drug level increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Left ventricular end-diastolic pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sputum culture positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bone lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus associated lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nephrosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mediastinal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mediastinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pleural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Excessive granulation tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incisional drainage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="262" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Heart transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="268"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="167"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="268"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

